St. Jude Medical, Inc. is pointing us at the presentation of important data around its SJM™ Quadra CRT System during the Heart Rhythm Society’s (HRS) 36th annual scientific sessions. Multiple presentations showcase improved clinical outcomes, increased survival and better cost utilization with the St. Jude Medical quadripolar cardiac resynchronization therapy (CRT) system.
St. Jude Medical introduced the industry’s first quadripolar CRT pacing system with the Quartet LV lead, featuring four uniquely spaced electrodes. The company says its quadripolar CRT pacing system offers physicians the ability to effectively and efficiently manage the ever-changing needs of patients with heart failure. The system integrates multiple pacing configurations that enable physicians to optimize the system at implant and follow-up, as well as better manage common pacing complications without having to surgically reposition the lead.
The HRS 36th annual scientific sessions see a few papers on the subject:
“Incremental Survival Benefit of High Percent Biventricular Pacing in Quadripolar CRT” was presented by Dr. Michael R. Gold, who led the study. The analysis looked at 8,973 patients with high and low percentages of biventricular (bi-v) pacing with the SJM Quadra CRT System, including the Quartet™ LV Lead, compared to a standard bipolar pacing lead. High bi-v pacing was defined as resynchronization pacing rates equal to or greater than 93 percent. The mortality benefit of quadripolar leads was observed in both the high and low percentages of bi-v pacing patient groups. In patients with a high percentage of bi-v pacing, the risk of mortality was 24 percent lower in those with a Quartet LV lead than those with a conventional bipolar lead.
Data was presented by Dr. Mintu P. Turakhia during a session titled Quadripolar LV leads are Associated with Decreased Shock Burden in CRT-D Patients. The analysis evaluated nearly 11,000 patients implanted with a CRT-D (8,640 with a quadripolar lead vs. 2,303 with a bipolar lead) found that the shock-free survival (chance of not getting an initial shock) was higher in patients implanted with the Quartet LV lead, showing a reduced risk of shocks by 13 percent compared to bipolar LV leads.
Additional data presentations for the St. Jude Medical quadripolar pacing system included Decreased Heart Failure Event Rates and associated Costs with Quadripolar versus Bipolar CRT-D systems, presented by Dr. Raffaele Corbisiero. These data showed that the Quartet LV lead exhibited a 31 percent reduction in post-implant heart failure hospitalization rates in the U.S. and a significant 39.8 percent reduction in associated costs compared to CRT-D patients with bipolar LV leads.
St. Jude says more than 130 publications now support its Quadra CRT System.
“These data show how our continued innovation demonstrates improved clinical and economic outcomes in cardiac resynchronization therapy,” said Dr. Mark D. Carlson, chief medical officer for St. Jude Medical. “The SJM Quadra CRT Systems are a key component of our leadership in heart failure solutions.”
Source: Business Wire